Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Vistra Corp (VST) vs Viatris Inc (VTRS) Price & Performance

Vistra CorpTrade
Viatris IncTrade

Price performance (Past 24H)

Key statistics

Vistra Corp vs Viatris Inc — how do they compare? Vistra Corp trades at $146.55 (market cap $48.64B), while Viatris Inc trades at $16.24 (market cap $18.69B). The key difference: Vistra Corp is far larger — about 2.6× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.95%). Which is the better fit depends on your goals.

VSTVTRS
Market Cap
$48.64B$18.69B
Sector
TechnologyHealth
52-Week High
$217.92$17.86
52-Week Low
$134.71$9.49
Enterprise Value
$70.58B$30.80B
Dividend Yield
0.63%2.95%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Vistra Corp

VST trades at $146.36, up 2.44% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported strong Q2 2026 earnings with $1.767 billion adjusted EBITDA, beating expectations, while maintaining 2026 guidance. Valuation metrics show a P/E of 24.44 and robust profitability with 75.73% ROE, though recent earnings have been inconsistent with two misses in the last four quarters.

VST presents a compelling growth story driven by data center power demand and nuclear assets, with 90.9% analyst buy ratings and a $239.75 price target suggesting 64% upside. Key risks include ERCOT pricing volatility and hedging losses, while institutional interest remains strong with recent strategic acquisitions positioning the company for AI infrastructure growth.

Viatris Inc

Viatris (VTRS) trades at $16.33, up 0.31% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q2 2026 EPS of $0.69, exceeding expectations, and revenue growth of 5% year-over-year. However, negative net income margins and a high P/E ratio of 236.2 highlight profitability challenges. Recent developments include FDA approval for Gwyn Lo contraceptive patch and ongoing divestitures to sharpen focus.

Outlook remains mixed: operational improvements and dividend payments offer stability, but persistent net losses and high debt pose risks. Analyst consensus leans Hold (61.54%), reflecting cautious optimism amid execution uncertainties. Investment appeal hinges on successful margin recovery and debt management in a competitive generic drug market.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Vistra Corp

Vistra is a leading integrated retail electricity and power generation company that serves as a critical infrastructure provider for the digital economy. It operates a diversified portfolio of zero-carbon nuclear and renewable assets alongside a massive, flexible natural gas fleet, positioning it as an indispensable partner for energy-intensive AI data centers and industrial electrification.

Read more on VST

About Viatris Inc

Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).

Read more on VTRS